Literature DB >> 22367168

Neuropeptide Y Y5 receptor antagonism attenuates cocaine-induced effects in mice.

Gunnar Sørensen1, Morten Jensen, Pia Weikop, Ditte Dencker, Søren H Christiansen, Claus Juul Loland, Cecilie Hee Bengtsen, Jørgen Holm Petersen, Anders Fink-Jensen, Gitta Wörtwein, David P D Woldbye.   

Abstract

RATIONALE: Several studies suggest a role for neuropeptide Y (NPY) in addiction to drugs of abuse, including cocaine. However, the NPY receptors mediating addiction-related effects remain to be determined.
OBJECTIVES: To explore the potential role of Y5 NPY receptors in cocaine-induced behavioural effects.
METHODS: The Y5 antagonist L-152,804 and Y5-knockout (Y5-KO) mice were tested in two models of cocaine addiction-related behaviour: acute self-administration and cocaine-induced hyperactivity. We also studied effects of Y5 receptor antagonism on cocaine-induced c-fos expression and extracellular dopamine with microdialysis as well as dopamine transporter-mediated uptake of dopamine in vitro. Immunocytochemistry was used to determine whether dopamine neurons express Y5-like immunoreactivity.
RESULTS: In self-administration, L-152,804 prominently decreased nose-poking for the peak dose of cocaine and shifted the dose-response curve for cocaine downward. Y5-KO mice also showed modestly attenuated self-administration. Cocaine-induced hyperactivity was attenuated by L-152,804 and in Y5-KO mice. Cocaine failed to increase c-fos expression in the nucleus accumbens and striatum of L-152,804-treated mice, indicating that the Y5 antagonist could act by influencing neural activity in these regions. Accordingly, the cocaine-induced increase in accumbal extracellular dopamine was attenuated by L-152,804 and in Y5-KO mice, suggesting that Y5 antagonism influences cocaine-induced behaviour by regulating dopamine. Consistent with this concept, dopamine neurons in the ventral tegmental area appeared to contain Y5 receptors. In contrast, neither L-152,804 nor NPY influenced dopamine transporter-mediated dopamine uptake.
CONCLUSIONS: The present data indicate that Y5 antagonism may attenuate cocaine-induced behavioural effects, suggesting that Y5 receptors could be a potential therapeutic target in cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367168     DOI: 10.1007/s00213-012-2651-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

1.  Regional distribution of Y-receptor subtype mRNAs in rat brain.

Authors:  R M Parker; H Herzog
Journal:  Eur J Neurosci       Date:  1999-04       Impact factor: 3.386

2.  The neuropeptide-Y Y5 receptor antagonist L-152,804 decreases alcohol self-administration in inbred alcohol-preferring (iP) rats.

Authors:  Jason P Schroeder; David H Overstreet; Clyde W Hodge
Journal:  Alcohol       Date:  2005-07       Impact factor: 2.405

3.  Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures.

Authors:  Casper R Gøtzsche; Litsa Nikitidou; Andreas T Sørensen; Mikkel V Olesen; Gunnar Sørensen; Søren H O Christiansen; Mikael Ängehagen; David P D Woldbye; Merab Kokaia
Journal:  Neurobiol Dis       Date:  2011-08-22       Impact factor: 5.996

4.  Intracerebroventricular administration of neuropeptide Y affects parameters of dopamine, glutamate and GABA activities in the rat striatum.

Authors:  L Kerkerian-Le Goff; C Forni; D Samuel; A Bloc; N Dusticier; A Nieoullon
Journal:  Brain Res Bull       Date:  1992-02       Impact factor: 4.077

Review 5.  A psychomotor stimulant theory of addiction.

Authors:  R A Wise; M A Bozarth
Journal:  Psychol Rev       Date:  1987-10       Impact factor: 8.934

6.  Modulation of [3H]Dopamine release from rat nucleus accumbens by neuropeptide Y may involve a sigma1-like receptor.

Authors:  D T Ault; J M Radeff; L L Werling
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

7.  Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors.

Authors:  Adepero Shola Adewale; Heather Macarthur; Thomas C Westfall
Journal:  Neuropharmacology       Date:  2007-02-20       Impact factor: 5.250

8.  Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain.

Authors:  Pia Weikop; Börje Egestad; Jan Kehr
Journal:  J Neurosci Methods       Date:  2004-12-30       Impact factor: 2.390

9.  Neuropeptide Y infusion into the shell region of the rat nucleus accumbens increases extracellular levels of dopamine.

Authors:  Gunnar Sørensen; Gregers Wegener; Jørgen Hasselstrøm; Thomas V O Hansen; Gitta Wörtwein; Anders Fink-Jensen; David P D Woldbye
Journal:  Neuroreport       Date:  2009-07-15       Impact factor: 1.837

10.  Increased amphetamine-induced locomotor activity, sensitization, and accumbal dopamine release in M5 muscarinic receptor knockout mice.

Authors:  Lene S Schmidt; Anthony D Miller; Deranda B Lester; Cecilie Bay-Richter; Christina Schülein; Henriette Frikke-Schmidt; Jürgen Wess; Charles D Blaha; David P D Woldbye; Anders Fink-Jensen; Gitta Wortwein
Journal:  Psychopharmacology (Berl)       Date:  2009-10-10       Impact factor: 4.530

View more
  15 in total

1.  An allosteric enhancer of M₄ muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine.

Authors:  Ditte Dencker; Pia Weikop; Gunnar Sørensen; David P D Woldbye; Gitta Wörtwein; Jürgen Wess; Anders Fink-Jensen
Journal:  Psychopharmacology (Berl)       Date:  2012-05-31       Impact factor: 4.530

2.  Neurotransmitter and psychostimulant recognition by the dopamine transporter.

Authors:  Kevin H Wang; Aravind Penmatsa; Eric Gouaux
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

3.  Neuropeptide y gates a stress-induced, long-lasting plasticity in the sympathetic nervous system.

Authors:  Qian Wang; Manqi Wang; Matthew D Whim
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

4.  The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice.

Authors:  Gunnar Sørensen; India A Reddy; Pia Weikop; Devon L Graham; Gregg D Stanwood; Gitta Wortwein; Aurelio Galli; Anders Fink-Jensen
Journal:  Physiol Behav       Date:  2015-06-11

5.  A novel dopamine transporter transgenic mouse line for identification and purification of midbrain dopaminergic neurons reveals midbrain heterogeneity.

Authors:  Mia Apuschkin; Sara Stilling; Troels Rahbek-Clemmensen; Gunnar Sørensen; Guillaume Fortin; Freja Herborg Hansen; Jacob Eriksen; Louis-Eric Trudeau; Kristoffer Egerod; Ulrik Gether; Mattias Rickhag
Journal:  Eur J Neurosci       Date:  2015-09-30       Impact factor: 3.386

6.  A C-terminal PDZ domain-binding sequence is required for striatal distribution of the dopamine transporter.

Authors:  Mattias Rickhag; Freja Herborg Hansen; Gunnar Sørensen; Kristine Nørgaard Strandfelt; Bjørn Andresen; Kamil Gotfryd; Kenneth L Madsen; Ib Vestergaard-Klewe; Ina Ammendrup-Johnsen; Jacob Eriksen; Amy H Newman; Ernst-Martin Füchtbauer; Jesus Gomeza; David P D Woldbye; Gitta Wörtwein; Ulrik Gether
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  Characterization of Highper, an ENU-induced mouse mutant with abnormal psychostimulant and stress responses.

Authors:  Amy F Eisener-Dorman; Janice S Bailey; Laura Grabowski-Boase; Salvador Huitron-Resendiz; Amanda J Roberts; Tim Wiltshire; Lisa M Tarantino
Journal:  Psychopharmacology (Berl)       Date:  2012-09-05       Impact factor: 4.530

Review 8.  Dopaminergic Regulation of Striatal Interneurons in Reward and Addiction: Focus on Alcohol.

Authors:  Rhona Clarke; Louise Adermark
Journal:  Neural Plast       Date:  2015-07-13       Impact factor: 3.599

9.  Addiction is a Reward Deficit and Stress Surfeit Disorder.

Authors:  George F Koob
Journal:  Front Psychiatry       Date:  2013-08-01       Impact factor: 4.157

10.  Enhanced inhibitory control by neuropeptide Y Y5 receptor blockade in rats.

Authors:  A Bari; A Dec; A W Lee; J Lee; D Song; E Dale; J Peterson; S Zorn; X Huang; B Campbell; T W Robbins; A R West
Journal:  Psychopharmacology (Berl)       Date:  2014-09-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.